An estimated 80% of obstructive sleep apnea cases in the US remain undiagnosed. At-home sleep testing could help close that gap, allowing more patients to be assessed without an overnight stay in a sleep lab. Beacon Biosignals is among the companies expanding access to clinical-grade sleep testing at home, building a platform that combines respiratory monitoring with EEG headbands and AI-powered sleep analysis.

On October 22, Beacon announced its acquisition of Snap Diagnostics, a nationwide provider of home sleep apnea testing. The deal more than doubles its patient reach, making it one of the largest home sleep testing providers in the US. It follows earlier acquisitions of CleveMed, a provider of home sleep testing equipment and services, in 2025, and Dreem’s R&D business, which developed the EEG headband now marketed as Waveband, in 2023.

Building out sleep diagnostics

Snap Diagnostics has been providing home sleep apnea testing since 1994. Its service allows physicians to order a sleep test without having to manage the process themselves. Snap ships the equipment directly to patients, while also handling insurance billing. Recordings are then interpreted by qualified sleep specialists. The Illinois-based company will continue operating under its existing brand as a Beacon subsidiary.

Beacon comes from a different corner of the sleep industry. Founded in 2019 by Jacob Donoghue and Jarrett Revels, the Boston-based company focuses on using EEG and machine learning to identify brain biomarkers for pharmaceutical research. Its partners include Johnson & Johnson, Bristol Myers Squibb, and Takeda, which Beacon recently helped secure FDA approval for its narcolepsy drug Orzeyful.

Read the full Deep Dive How Neurotech Monitors and Modulates Sleep A map of how neurotech is moving sleep beyond proxy tracking, from EEG and fNIRS wearables to adaptive stimulation and clinical sleep devices.

Backed by more than $132 million in funding, including a $97 million Series B completed earlier this year, Beacon has increasingly expanded into clinical diagnostics. Its 2023 acquisition of Dreem's R&D business brought EEG headband technology, while CleveMed added respiratory monitoring devices and an established home testing service. The latter now reports more than 4,500 active users of its SleepView Direct service.

“Snap gives us the national reach to bring EEG-enabled testing to nearly every clinician who sees patients at risk for sleep disorders," says Beacon CEO Jacob Donoghue. "We believe sleep diagnostics will soon extend well beyond sleep apnea, with the potential for at-home neurophysiology to help identify early signs of neurodegenerative disease and support more personalized psychiatric care. This acquisition is a major step toward that future.”

EEG-based sleep testing

Most home sleep apnea tests monitor breathing but lack EEG to measure brain activity. As a result, these tests often cannot distinguish between sleep and wakefulness. This means that breathing interruptions may be averaged over the entire recording--including periods when patients are awake--making sleep apnea appear less severe. Beacon's FDA-cleared Waveband headband could help address this limitation by directly measuring sleep and wakefulness.

Beyond distinguishing sleep from wakefulness, Waveband also tracks different stages of sleep. In a 2026 multicenter study, the headband achieved 87.3% agreement with expert sleep-stage scoring, comparable to the 85.9% average agreement among human scorers.

Beacon plans to make EEG-enabled sleep testing more widely available in 2027.

Read the full piece Nyxoah advances neuromodulation for sleep apnea Nyxoah advances Genio in the U.S. with ACCCESS and BREATHE milestones, while expanding its sleep apnea label, commercial footprint, and financing base in 2026.

Neurotechnology is also advancing on the treatment side of sleep medicine. Companies such as Nyxoah are developing neuromodulation treatments for obstructive sleep apnea, using hypoglossal nerve stimulation to keep the upper airway open during sleep.